Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma

International Journal of Cancer

Volumn 121, Issue 7, 2007, Pages 1600-1608

  Dua, Pooja ^a   Ingle, Arvind ^a   Gude, Rajiv P ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

B16F10 melanoma; Combination therapy; Metastasis; Pentoxifylline; Suramin

Indexed keywords

COLLAGEN TYPE 4; GELATINASE B; LAMININ; MATRIGEL; PENTOXIFYLLINE; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL MOTILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; EXTRACELLULAR MATRIX; LAMININ; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NIH 3T3 CELLS; PENTOXIFYLLINE; PROTEOGLYCANS; SURAMIN; TIME FACTORS;

EID: 34548203180     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22843     Document Type: Article

References (46)

1. Jemal A, Devesa SS, Fears TR, Hartge P. Cancer surveillance series: changing patterns of cutaneous malignant melanoma mortality rates among whites in the United States. J Natl Cancer Inst 2000;92:811-18.
2. Hauschild A, Osterkamp G, Clausen M, Christophers E. [Dramatic remission of a multiple metastasized melanoma caused by chemoimmunotherapy]. Dtsch Med Wochenschr 1993;118:336-40.
3. Gude RP, Ingle AD, Rao SG. Inhibition of lung homing of B16F10 by pentoxifylline, a microfilament depolymerizing agent. Cancer Lett 1996;106:171-6.
4. Dua P, Gude RP. Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol 2006;58:195-202.
5. Gude RP, Binda MM, Boquete AL, Bonfil RD. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol 2001;127:625-30.
6. Li YX, Sun LQ, Weber-Johnson K, Paschoud N, Coucke PA. Potentiation of cytotoxicity and radiosensitization of (E)-2-deoxy-2′-(fluoromethylene) cytidine bv pentoxifylline in vitro. Int J Cancer 1999;80:155-60.
7. Lazarczyk M, Grzela T, Niderla J, Lazarczyk MA, Milewski L, Dziunycz P, Skopinski P, Golab J. Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. Oncol Rep 2004;11:1121-5.
8. Nicholson CD, Challiss RA, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991;12:19-27.
9. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ, Hsieh BS. Inhibition by pentoxifylline of TNF-α-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-κB down-regulation. Br J Pharmacol 2003;138:950-8.
10. Ji Q, Zhang L, Jia H, Xu J. Pentoxifylline inhibits endotoxin-induced NF-κB activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci 2004;34:427-36.
11. Labrousse AL, Ntayi C, Hornebeck W, Bernard P. Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol 2004;49:269-75.
12. Klijn JG, Setyono-Han B, Bakker GH, van der Burg ME, Bontenbal M, Peters HA, Sieuwerts AM, Berns PM, Foekens JA. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. J Steroid Biochem Mol Biol 1990;37:1089-95.
13. Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 2003;104:167-74.
14. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE. Nature of the interaction of growth factors with suramin. Biochemistry 1992;31:9016-24.
15. Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-9.
16. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61:2533-6.
17. Dreicer R, Smith DC, Williams RD, See WA. Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 1999;17:183-6.
18. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer 2004;100:65-71.
19. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
20. Song S, Yu B, Wei Y, Wientjes MG, Au JL. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 2004;10(18, Part 1):6058-65.
21. Meyer M, Jeong E, Bolinger B, Chen L, Lenehan P, Slichenmyer W, Natale RB. Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer. Am J Clin Oncol 2001;24:167-71.
22. Sola F, Farao M, Marsiglio A, Mariani M, Grandi M. Inhibition of lung and liver tumor colonies in mice pretreated with suramin. Invasion Metastasis 1993;13:163-8.
23. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL, Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991;266:9661-6.
24. Halaban R. Growth factors and melanomas. Semin Oncol 1996;23:673-81.
25. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973;242:148-9.
26. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 2004;28:91-5.
27. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB- mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001;276:44926-35.
28. Basu A, Kligman LH, Samulewicz SJ, Howe CC. Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40). BMC Cell Biol 2001;2:15.
29. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
31. McNally WP, DeHart PD, Lathia C, Whitfield LR. Distribution of [14C]suramin in tissues of male rats following a single intravenous dose. Life Sci 2000;67:1847-57.
32. Srinivasu P, Rao BR, Rao YM, Rambhau D. Circadian variations in the pharmacokinetics of pentoxifylline in man. J Pharm Pharmacol 1998;50:71-4.
33. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
34. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-57.
35. Bennewith KL, Durand RE. Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity. Br J Cancer 2001;85:1577-84.
36. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-217.
37. Liefner M, Maruschak B, Bruck W. Concentration-dependent effects of pentoxifylline on migration and myelin phagocytosis by macrophages. J Neuroimmunol 1998;89:97-103.
38. Yunes R, Fernandez P, Doncel GF, Acosta AA. Cyclic nucleotide phosphodiesterase inhibition increases tyrosine phosphorylation and hyper motility in normal and pathological human spermatozoa. Biocell 2005;29:287-93.
39. Dominguez-Jimenez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F, Gonzalez-Amaro R. Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol 2002;71:588-96.
40. Schilling-Schon A, Pleyer U, Hartmann C, Rieck PW. The role of endogenous growth factors to support corneal endothelial migration after wounding in vitro. Exp Eye Res 2000;71:583-9.
41. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
42. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 (Suppl):S42-S51.
43. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 1991;145:199-202.
44. Walz TM, Abdiu A, Wingren S, Smeds S, Larsson SE, Wasteson A. Suramin inhibits growth of human osteosarcoma xenografts in nude mice. Cancer Res 1991;51:3585-9.
45. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004;24:233-47.
46. Coimbra R, Porcides RD, Melbostad H, Loomis W, Tobar M, Hoyt DB, Wolf P. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg Infect (Larchmt) 2005;6:73-85.